Assembly Bio Q1 FY26 net loss narrows to $9.1 million; revenue slips to $8.2 million

Assembly Biosciences, Inc.

Assembly Biosciences, Inc.

ASMB

0.00
  • Assembly Biosciences posted a net loss attributable to common stockholders of USD 9.1 million, or USD 0.54 per share, for the first quarter ended March 31, 2026.
  • Revenue from collaborative research with Gilead fell 12.81% to USD 8.2 million.
  • Research and development expenses were little changed at USD 14.9 million, while general and administrative costs rose to USD 4.7 million.
  • Cash, cash equivalents and marketable securities slipped to USD 226.6 million; cash runway projected to fund operations into 2028.
  • Completed Phase 1b follow-up for ABI-5366 and ABI-1179; decision due by mid-2026 on opting into a 40% U.S. cost-profit share with Gilead, with Phase 2 start for ABI-6250 in chronic hepatitis delta virus expected in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605071600PRIMZONEFULLFEED9715047) on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.